Zacks Research Brokers Lift Earnings Estimates for TSE:BHC

Bausch Health Companies Inc. (TSE:BHC) – Equities researchers at Zacks Research boosted their Q2 2026 earnings per share (EPS) estimates for Bausch Health Companies in a report issued on Friday, July 24th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.35 for the quarter, up from their previous forecast of $1.31. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $5.54 EPS and Q1 2027 earnings at $1.13 EPS.

Separately, Jefferies Financial Group upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of “Hold”.

Bausch Health Companies Stock Performance

Shares of TSE BHC opened at C$6.40 on Monday. The firm’s 50-day moving average price is C$6.98 and its 200-day moving average price is C$7.60. Bausch Health Companies has a 52-week low of C$6.10 and a 52-week high of C$11.97. The company has a market cap of C$2.39 billion, a PE ratio of -1.98, a PEG ratio of 0.21 and a beta of 0.97. The company has a quick ratio of 0.58, a current ratio of 1.32 and a debt-to-equity ratio of -1,009.96.

Bausch Health Companies (TSE:BHC) last issued its earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. The business had revenue of C$3.51 billion during the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.

Key Headlines Impacting Bausch Health Companies

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Alberta reimbursement expands access to Elidel: Elidel (pimecrolimus) cream is now reimbursed under Alberta’s public drug plan for eligible patients with mild to moderate atopic dermatitis. The broader coverage could improve product access, prescriptions and revenue for Bausch Health’s dermatology business. Elidel Reimbursement Announcement
• Positive Sentiment: Zacks Research raised several earnings projections: The analyst lifted its estimates for third-quarter 2026 EPS to $1.47 from $1.42, second-quarter 2027 EPS to $1.16 from $1.13, third-quarter 2027 EPS to $1.47 from $1.43, and fourth-quarter 2027 EPS to $1.33 from $1.30. Full-year 2027 EPS was increased to $5.10 from $4.97, while full-year 2028 EPS rose to $4.34 from $4.24. The revisions suggest improving expectations for Bausch Health’s future earnings power. Bausch Health Earnings Estimates
• Neutral Sentiment: Analysts set expectations for second-quarter earnings: A separate research report reviewed expectations for BHC’s upcoming second-quarter results. The current consensus cited in the reports is approximately $5.55 in EPS for the full year, providing a benchmark for investors ahead of future results. Equities Analysts Set Expectations for BHC Q2 Earnings
• Negative Sentiment: One estimate was trimmed: Zacks lowered its first-quarter 2028 EPS forecast to $0.81 from $0.82. The small reduction is not material by itself, but it partially offsets the broader series of upward revisions. BHC also continues to trade near its one-year low and below its 50-day and 200-day moving averages, reflecting ongoing investor concerns about its balance sheet and profitability.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.